the aid library

LIST OPTIONS

Filter

4801

Pharmaceutical pollution of the world’s rivers

Wilkinson, J.L.; A.B. A. Boxall, D. W. Kolpin, et al. (2022) CC

PNAS 119 (8) e2113947119 | https://doi.org/10.1073/pnas.2113947119 Environmental exposure to active pharmaceutical ingredients (APIs) can have negative effects on the health of ecosystems and humans. While numerous studies have monitored APIs in rivers, these employ different analytical methods, m... more

External Link

Health Care Facilities Resilient to Climate Change Impacts

Paterson, J.; P. Berry, K. Ebi and L. Varangu (2014) CC

nt. J. Environ. Res. Public Health 2014, 11(12), 13097-13116; https://doi.org/10.3390/ijerph111213097 Climate change will increase the frequency and magnitude of extreme weather events and create risks that will impact health care facilities. Health care facilities will need to assess climate chang... more

External Link

Monitoring the elimination of human African trypanosomiasis at continental and country level: Update to 2018

Franco, JR.; Cecchi, G.; Priotto, G.; Paone, M.; Diarra, A. et al. (2020) CC

Over the past twenty years, huge efforts made by a broad coalition of stakeholders curbed the last epidemic and brought the disease to the brink of elimination. In this paper, the latest figures on disease occurrence, geographical distribution and control activities are presented. Strong evidence in... more

External Link

Laboratory techniques in rabies

Rupprecht, C.; Fooks, A,; Abela-Ridder, B. World Health Organization WHO (2018) C_WHO

Rabies has an enormous impact on both agriculture and conservation biology, but its greatest burden is undeniably on public health. As such, routine methods for rapid risk assessment after human exposures to rabies as well as applications for laboratory-based surveillance, production of biologicals ... more

External Link

Global programme to eliminate lymphatic filariasis: progress report, 2020 - Weekly Epidemiological Record, 2021, vol. 96, 41 [‎full issue]‎

World Health Organization WHO; Institutional research information sharing iris (2021) C_WHO

Lymphatic filariasis (LF) is an avoidable, debilitating, disfiguring disease caused by infection with the filarial parasites Wuchereria bancrofti, Brugia malayi and B. timori. Globally, 51.4 million people are estimated to be infected. Lymphoedema and hydrocoele are the visible, chronic clinical co... more

Kangaroo mother care - Implementation strategy for scale-up adaptable to different country contexts

World Health Organisation (WHO) (2023) C_WHO

The KMC implementation strategy targets a broad audience. These include policy-makers and programme managers at national, regional and local levels, government and nongovernmental organizations working in the area of maternal and newborn care, global and national professional associations, public an... more

External Link

Stark choices: exploring health sector costs of policy responses to COVID-19 in low-income and middle-income countries

Torres-Rueda S.; S. Sweeney; F. Bozzani et al. BMJ Global Health (2021) C2

COVID-19 has altered health sector capacity in low-income and middle-income countries (LMICs). Cost data to inform evidence-based priority setting are urgently needed. Consequently, in this paper, we calculate the full economic health sector costs of COVID-19 clinical management in 79 LMICs under di... more

Download (173)

View PDF (283)

Urban flood risk handbook: Assessing risk and identifying interventions

Ferguson, S.; Van Ledden, M.; Rubinyi, S.; Campos, A.; Doeffinger, T. World Bank (2023) CC

This Urban Flood Risk Handbook: Assessing Risk and Identifying Interventions is a roadmap for conducting an urban flood risk assessment in any city in the world. It includes practical guidance for a flood risk assessment project, covering the key hazard and risk modeling stages as well as the evalua... more

Download (167)

View PDF (302)

Voluntary non-remunerated blood donations to ensure blood safety in the WHO South-East Asia Region to support universal health coverage

World Health Organisation (WHO) (2023) C_WHO

Access to safe blood and blood products is recognized as one of the key requirements for delivery of modern health care in the journey towards health for all. The foundation of safe and sustainable blood supplies depends on the collection of blood from voluntary non-remunerated and low-risk donors. ... more

Trends in the alignment and harmonization of reproductive, maternal, newborn, and child health funding, 2008–13

Martinez-Alvarez M.; Achary A.; Arregoces L. et al. Health Affairs (2017) CC

Donor financing to low- and middle-income countries for reproductive, maternal, newborn, and child health increased substantially from 2008 to 2013. However, increased spending by donors might not improve outcomes, if funds are delivered in ways that undermine countries’ public financial managemen... more

Ready to Use Therapeutic Food (RUFT) and the WHO Essential Medicines List

CMAM Forum (2018) CC

Severe Acute Malnutrition (SAM) is one of the greatest child survival challenges in the world today and reportedly affects more than 16.2 million children each year1. High impact, proven treatment interventions exist yet sadly approximately only 3.2 million children with SAM have access to treatme... more

WHO package of essential noncommunicable (PEN) disease interventions for primary health care

World Health Organization (WHO) World Health Organization (WHO) (2020) C_WHO

The "WHO Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care" provides a set of cost-effective, evidence-based interventions to address noncommunicable diseases (NCDs) such as cardiovascular diseases, diabetes, chronic respiratory diseases, and cancers. Designed ... more

The ISN framework for developing dialysis programs in low-resource settings

International Society of Nephrology (2021) CC2

Chronic kidney disease (CKD) is an important contributor to mortality from noncommunicable diseases. No decrease has been seen for CKD mortality contrary to many other important non-communicable diseases (e.g., cardiovascular disease). The prevalence of CKD and kidney failure are increasing all over... more

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Job satisfaction among healthcare workers in Ghana and Kenya during the COVID-19 pandemic: Role of perceived preparedness, stress, and burnout

Afulani PA, Nutor JJ, Agbadi P, Gyamerah AO, Musana J, Aborigo RA, et al. PLOS Global Public Health (2021) CC

The COVID-19 pandemic has affected job satisfaction among healthcare workers; yet this has not been empirically examined in sub-Saharan Africa (SSA). We addressed this gap by examining job satisfaction and associated factors among healthcare workers in Ghana and Kenya during the COVID-19 pandemic. W... more

Good Practices in the Rational and Effective Use of Oxygen
recommended

Pan American Health Organisation PAHO PAHO (2021) C_WHO

In the face of rapid increases in the number of hospitalizations due to COVID-19 in Latin America and the Caribbean, coupled with shortages of human and material resources, including medical equipment and gases, there is a need to redesign models of care in the Region to optimize available resources... more

External Link

Climate Change and Pollen Allergies

Damialis, A.; Traidl-Hoffmann, C.; Treudler, R. (2019) CC

Biodiversity and Health in the Face of Climate Change pp 47–66 This chapter reviews the emerging importance of pollen allergies in relation to ongoing climate change. Allergic diseases have been increasing in prevalence over the last decades, partly as the result of the impact of climate change. ... more

External Link

Dengue Clinical Case Management course (DCCM)

Centers for Disease Control and Prevention CDC (2020) C_CDC

PROGRAM DESCRIPTION: Course is designed to increase knowledge and develop competency in the management of patients suspected of infection with dengue virus.

External Link

Self-learning course: Clinical diagnosis and management of dengue

Pan American Health Organization PAHO ; World Health Organization WHO (2021) C_WHO

This first online course is geared at helping healthcare workers in diagnosing and managing all aspects of dengue in order to avoid complications and fatalities. This course was developed with a comprehensive vision. It is divided into seven modules that include: Epidemiological informatio... more

Download (8921)

View PDF (9576)

Ebola Outbreak Preparedness & Management

Baert, B. MSF (2001) C1

Good Practices in the Rational and Effective Use of Oxygen recommended

Good Practices in the Rational and Effective Use of Oxygen
recommended